ArticleAnnals of medicine2023

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.

Yao Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.